Top Markets
#1 Wibx Wibx +8.04%
#2 Wrapped Flare Wrapped Flare +4.46%
#3 Decred Decred +4.31%
#4 Humanity Humanity +4.26%
#5 Across Protocol Across Protocol +3.82%
#6 Pearl Pearl +3.51%
#7 aelf aelf +3.44%
#8 Audiera Audiera +2.66%
#9 MarsCoin MarsCoin +2.24%
#10 TRIA TRIA +2.06%
Coin of the day
Wibx Wibx
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Clovis Oncology, Inc. Clovis Oncology, Inc.

Clovis Oncology, Inc.

C6O
Rang in Aktien #30761
Clovis Oncology, Inc. is a biopharmaceutical company focused on the discovery,... Clovis Oncology, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of anti-cancer agents, serving markets in the United States, Europe, and globally. Its flagship commercial product in the U.S. is Rubraca (rucaparib), an oral small molecule designed to inhibit poly ADP-ribose polymerase. This treatment is indicated for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, Rubraca is offered for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company's pipeline includes lucitanib, an investigational angiogenesis inhibitor that targets vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3). Also under development is FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent that specifically acts upon fibroblast activation protein. Rubraca is distributed through a select network of specialty distributors and pharmacies, which then supply the medication to patients and healthcare providers. Clovis Oncology has established strategic collaborations, including license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH. The company also maintains a clinical collaboration with Bristol Myers Squibb Company and a partnership with Foundation Medicine, Inc. Founded in 2009, Clovis Oncology, Inc. is headquartered in Boulder, Colorado.
Aktienkurs
$0.10794012
Zuletzt synchronisiert: 2022-12-15
Marktkapitalisierung
$15.65M
Veränderung (1 Tag)
-17.06%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Clovis Oncology, Inc. (C6O)

Kategorie

Healthcare
Preis C6O mit Marktkapitalisierung von B
Clovis Oncology, Inc. Clovis Oncology, Inc.
C6O
$0.10794012
Marktkapitalisierung von Clovis Oncology, Inc.(C6O)
Marktkapitalisierung: $15.65M
Mit Stand August 2026 hat Clovis Oncology, Inc. eine Marktkapitalisierung von $15.65M. Das macht Clovis Oncology, Inc. laut unseren Daten zum 30761st wertvollsten Unternehmen der Welt nach Marktkapitalisierung. Die Marktkapitalisierung ist der Gesamtmarktwert aller ausstehenden Aktien eines börsennotierten Unternehmens und wird häufig verwendet, um den Unternehmenswert zu bestimmen.
Marktkapitalisierung von Clovis Oncology, Inc. von 2019 bis 2026
C6O im Vergleich zu den Top 5 der beliebtesten stocks
Preis für C6O Vermögenswert B Marktkapitalisierung von B Ergebnisse
Clovis Oncology, Inc. Clovis Oncology, Inc.
$36,608.46 $15.65M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.307T +33,915,422.95%
Clovis Oncology, Inc. Clovis Oncology, Inc.
$31,394.09 $15.65M
Apple Inc. Apple Inc.
AAPL
$4.551T +29,084,627.94%
Clovis Oncology, Inc. Clovis Oncology, Inc.
$28,659.67 $15.65M
Alphabet Inc. Alphabet Inc.
GOOG
$4.154T +26,551,350.44%
Clovis Oncology, Inc. Clovis Oncology, Inc.
$24,756.27 $15.65M
Microsoft Corporation Microsoft Corporation
MSFT
$3.589T +22,935,091.10%
Clovis Oncology, Inc. Clovis Oncology, Inc.
$19,294.58 $15.65M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.797T +17,875,163.56%